ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AstraZeneca licenses another Daiichi cancer drug

by Michael McCoy
August 2, 2020 | APPEARED IN VOLUME 98, ISSUE 30

 

AstraZeneca will pay $1 billion, plus potential milestone payments, to develop DS-1062, a cancer-fighting antibody-drug conjugate (ADC) from Daiichi Sankyo. The deal is the second between the two firms. In March 2019, AstraZeneca paid $1.35 billion to develop Enhertu, another Daiichi ADC. Both molecules use Daiichi’s DXd technology for attaching an antibody to a cytotoxic agent with a tetrapeptide linker designed to be broken down by enzymes made by tumor cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment